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Introduction
The RASopathies are a heterogenous group of developmental disorders with overlapping phenotypic 
features that include craniofacial dysmorphism, short stature, developmental delay, learning disabili-
ties, neurocutaneous abnormalities, cardiovascular defects, and a variable risk of tumorigenesis (1–4). 
This group includes the common genetic disorders Noonan syndrome (NS) and neurofibromatosis 
1 type 1 (NF1) as well as Costello (CS), Cardio-Facio-Cutaneous (CFC), Legius, LEOPARD, and 
Noonan-like syndrome with loose anagen hair (NSLH). The discovery of germline mutations in RAS 
and in genes encoding other proteins involved in Raf/MEK/ERK (MAPK) signaling delineated dys-
regulation of this pathway as a unifying mechanism underlying the RASopathy disorders and uncov-
ered a key role of MAPK activation in regulating cell fate decisions in multiple developing tissues (1–3).
Somatic KRAS mutations that introduce amino acid substitutions at codons 12, 13, and 61 are highly 
prevalent in cancer and encode oncoproteins that accumulate in the active, GTP-bound conformation due to 
reduced rates of intrinsic GTP hydrolysis and resistance to GTPase-activating proteins (GAPs) (5). Endog-
enous expression of the most common of these somatic mutations in mice (KrasG12D) results in lethality by 
E14.5 due to cardiovascular and hematopoietic defects (6). Lung branching morphogenesis is also profoundly 
Somatic KRAS mutations are highly prevalent in many cancers. In addition, a distinct spectrum of 
germline KRAS mutations causes developmental disorders called RASopathies. The mutant proteins 
encoded by these germline KRAS mutations are less biochemically and functionally activated than 
those in cancer. We generated mice harboring conditional KrasLSL-P34Rand KrasLSL-T58I knock-in alleles and 
characterized the consequences of each mutation in vivo. Embryonic expression of KrasT58I resulted in 
craniofacial abnormalities reminiscent of those seen in RASopathy disorders, and these mice exhibited 
hyperplastic growth of multiple organs, modest alterations in cardiac valvulogenesis, myocardial 
hypertrophy, and myeloproliferation. By contrast, embryonic KrasP34R expression resulted in early 
perinatal lethality from respiratory failure due to defective lung sacculation, which was associated 
with aberrant ERK activity in lung epithelial cells. Somatic Mx1-Cre–mediated activation in the 
hematopoietic compartment showed that KrasP34R and KrasT58I expression had distinct signaling effects, 
despite causing a similar spectrum of hematologic diseases. These potentially novel strains are robust 
models for investigating the consequences of expressing endogenous levels of hyperactive K-Ras in 
different developing and adult tissues, for comparing how oncogenic and germline K-Ras proteins 
perturb signaling networks and cell fate decisions, and for performing preclinical therapeutic trials.
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abnormal in these embryos. The K-Ras proteins encoded by causative NS and CFC syndrome mutations are 
less activated biochemically and functionally than K-RasG12D (7, 8). Of these, a valine-to-isoleucine substitu-
tion at codon 14 (V14I) is among the most common and biochemically least deleterious K-Ras alterations (7) 
(https://nseuronet.com/php/about.php). Hernández-Porras and colleagues generated and comprehensively 
characterized a strain of KrasV14I knock-in mice (9). Heterozygous mutant animals were born at the expected 
Mendelian ratio, survived to adulthood, and showed modest NS-like developmental abnormalities. These 
phenotypes were more pronounced in homozygous KrasV14I mice, which also had impaired perinatal growth 
and survival. We reasoned that modeling additional germline KRAS mutations with different effects on intrin-
sic GTP hydrolysis and responses to GAPs would advance our current understanding of activated Ras signal-
ing in development and tumorigenesis while also generating mouse strains for biologic studies and preclinical 
drug testing. Germline mutations that result in P34R and T58I amino acid substitutions were of particular 
interest due to the clinical characteristics of affected children and the biochemical properties of these proteins.
In 1993, a proline-to-arginine (P34R) mutation was isolated from an unbiased screen in yeast to identify 
activating substitutions in the c-H-Ras effector domain (10). P34 is located within the interacting interface of 
the Ras switch I domain that contacts GAPs, guanine nucleotide exchange factors, and other Ras effectors 
such as Raf (11, 12). Recombinant K-RasP34R has normal intrinsic hydrolysis but is insensitive to GAP stimula-
tion (8). The P34R substitution also reduces the affinity of Ras for Raf (11, 12). Despite this, K-RasP34R induced 
greater activation of MAPK signaling when overexpressed in COS-7 cells than other RASopathy mutations 
and also caused pronounced cytokine sensitivity in transduced hematopoietic progenitor cells (7, 8). The first 
reported patient with a germline KRASP34R mutation exhibited clinical features suggestive of CFC syndrome, 
including severe developmental delay and congenital heart defects (7).
T58 is almost completely buried when Ras is in the active, GTP-bound state, and it is not predicted to 
directly participate in the interaction with Ras-binding partners (11). However, in silico structural modeling 
suggested that T58 may undergo significant rearrangements between the active and inactive conformations 
and that insertion of a methyl group by the isoleucine substitution might also alter the structural integrity of 
the protein. Recombinant K-RasT58I is characterized by defective intrinsic GTPase activity and reduced GAP- 
mediated GTP hydrolysis (7, 11). The index patient with a germline KRAS T58I mutation had NS with a 
severe clinical phenotype (7). At 3 months of age, she developed a myeloproliferative neoplasm (MPN) with 
features of juvenile myelomonocytic leukemia (JMML) that resolved without treatment. Somatic KRASP34R 
and KRAST58I mutations have also been identified in some cancers, with the KRAST58I mutation mostly found in 
sporadic myeloid leukemias (https://cancer.sanger.ac.uk/cosmic) (13).
Additional individuals with the KRASP34R and KRAST58I mutations were subsequently identified and clini-
cally diagnosed with either CFC syndrome (most patients with KRASP34R mutations) or NS (most patients with 
KRAST58I mutations) (https://nseuronet.com/php/about.php). Based on the distinct clinical phenotypes of the 
respective patients, the potentially novel biochemical and functional properties of K-RasP34R and K-RasT58I, and 
the presence of recurrent somatic KRASP34R and KRAST58I mutations in cancer, we generated mice harboring 
conditional mutant P34R and T58I alleles and characterized their developmental, biochemical, and functional 
consequences. Here, we show that heterozygous mutant mice model key RASopathy phenotypes and show 
that each mutation has distinct and context-dependent effects on signal transduction.
Results
KrasT58I/+ mice develop multiple RASopathy phenotypes. We independently introduced conditional P34R and 
T58I mutations into the Kras locus of embryonic stem cells along with an inhibitory LoxP-STOP-LoxP (LSL) 
cassette (14) (Supplemental Figure 1A and Supplemental Figure 2A; supplemental material available online 
with this article; https://doi.org/10.1172/jci.insight.140495DS1). Blastocyst injections resulted in multiple 
coat color chimeras that were bred to WT C57BL/6 (B6) mice and selected for agouti offspring to achieve 
germline transmission of the KrasLSL-P34R and KrasLSL-T58I alleles (Supplemental Figure 1B and Supplemental 
Figure 2B). We then backcrossed these mice to a B6 strain background before mating them with a CMV-Cre 
transgenic strain (also on the B6 background) to broadly excise the LSL cassette and induce KrasP34R and 
KrasT58I expression early in embryogenesis (15) (Supplemental Figure 1C and Supplemental Figure 2C).
CMV-Cre KrasLSL-T58I mice appeared healthy and were fertile. We mated them with WT mice on a 
129S4 strain (129 strain) background, selected for offspring that inherited the KrasT58I allele but not the 
CMV-Cre transgene, and then generated and characterized additional KrasT58I/+ mice on B6, 129, and 
mixed strain backgrounds. KrasT58I/+ mice were born at a lower than expected ratio when backcrossed to 
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the B6 background, and viability decreased from 36% to 18% upon 2 backcrosses (Supplemental Table 
1). By contrast, mutant viability increased from 31% to 50% after 2 generations of backcrossing into the 
129/S4 background. We did not obtain any homozygous KrasT58I/T58I offspring from intercrossing KrasT58I/+ 
mice. Liveborn mice on all strain backgrounds appeared well, despite widespread KrasT58I expression.
Neonatal KrasT58I/+ mice had a modest decrease in body weight (Figure 1A) and length (data not shown) 
that resolved by 6 weeks of age and also exhibited facial dysmorphia (Figure 1B). We euthanized a cohort 
of KrasT58I/+ male mice on a C57BL/6J/129S4 (B6/129) F1 background at 8 months of age to investigate 
the consequences of this mutation in adult animals. Micro-computed tomography (μ-CT) imaging revealed 
synostosis of the coronal and interfrontal (metopic) sutures (Figure 1C) as well as a significantly increased 
cranial vault length, interzygomatic root width, interorbital width, and interzygomatic arch width (Sup-
plemental Figure 3C). The remaining cranial measurements were not significantly different from those of  
WT littermates (Supplemental Figure 3C), suggesting that synostosis of the coronal and interfrontal sutures 
contributes to the facial dysmorphia in KrasT58I/+ mice. Correspondingly, craniosynostosis has been report-
ed in patients with NS carrying the germline KRAST58I mutation (16).
Eight-month-old KrasT58I/+ mice had enlarged hearts and elevated heart weight–to–body weight ratios 
in comparison with their WT littermates (Figure 2A). Histological analysis revealed substantial thicken-
ing of the ventricular wall and septum (Figure 2A). Similarly, hypertrophic cardiomyopathy occurs in 
patients with RASopathy, particularly those with germline RAF1 and RIT1 mutations as well as in mouse 
models carrying mutations in these genes (17–19). While the kidneys and testes of KrasT58I/+ mice were also 
enlarged, normal tissue morphology was preserved (Supplemental Figure 4, A and B). Despite the high 
frequency of somatic KRAS mutations in pancreatic and lung adenocarcinoma (20), we did not observe 
histologic abnormalities in either tissue (data not shown).
KrasT58I/+ mice also developed splenomegaly (Figure 2B), which is consistent with the transient JMML-
like MPN in the index KRAST58I patient and the presence of somatic KRAST58I mutations in some hematologic 
Figure 1. Developmental phenotypes in KrasT58I/+ mice. (A) Growth curves of WT and KrasT58I/+ littermates on a mixed B6/129 strain background: WT male mice (n = 
22); WT female mice (n = 20); KrasT58I/+ male mice (n = 11); KrasT58I/+ female mice (n = 20). Error bars represent mean ± SEM. Statistical significance was evaluated by 
Student’s t test. **P < 0.01. (B) Typical facial morphology of WT and KrasT58I/+ male mice. (C) Micro-CT imaging of the skulls from WT and KrasT58I/+ male mice at 8 
months of age, showing craniosynostosis of the interfrontal and coronal sutures in mutant animals. Scale bar: 10 mm (top); original magnification, ×2.87 (bottom).
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Figure 2. Organ enlargement in 6- to 8-month-old KrasT58I/+ mice. (A) Gross appearance (top) and heart weight–to–body weight ratios (middle) of WT 
mice (n = 9, 7 male and 2 female mice) and their KrasT58I/+ littermates (n = 8, 6 male and 2 female mice). Mean ± SEM. Hearts were stained with Masson’s 
trichrome, and transverse sections were made at the papillary muscle level (bottom). RV, right ventricle; LV, left ventricle; IVS, interventricular septum. 
Asterisks indicate the papillary muscle. (B) Gross appearance (top), weights (mean and SEM are shown; middle), and representative histologic appearance 
(bottom) of representative spleens from WT and KrasT58I/+ mice. The mice analyzed were on either a F1 B6/129 (white circles or squares) or mixed B6/129 
strain (colored circles or squares) background. Note expanded red pulp, with increased myeloid elements, in KrasT58I/+ spleens. Scale bar: 120 μM; 60 μM  
(for insets). Statistical significance was evaluated by Student’s t test.
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malignancies (7, 13). Histologic analysis revealed increased splenic red pulp with infiltration of a mixture of 
myeloid cells (Figure 2B) (4, 7). In addition, the blood leukocyte counts of adult KrasT58I/+ mice were signifi-
cantly elevated because of  markedly increased numbers of neutrophils, lymphocytes, and monocytes (Sup-
plemental Figure 5A and Supplemental Table 2). We also observed increased numbers of morphologically 
normal BM myeloid cells (Supplemental Figure 5, B and C); this was confirmed by flow cytometric analysis, 
which showed a significant increase in the frequency of mature neutrophils (Gr1+Mac1+) (Supplemental Fig-
ure 5D) as well as of Mac1+ cells at all stages of myeloid differentiation (Supplemental Figure 5E). Although 
KrasT58I/+ mice had normal hemoglobin values (Supplemental Table 2), there was a reduction in the frequency 
of Ter119+ BM erythroid cells, particularly the Ter119hiCD71hi basophilic erythroblast population (Supple-
mental Figure 5, F and G). Multiparameter flow cytometric analysis of KrasT58I/+ BM mononuclear cells also 
revealed an increase in the frequencies of the ckit+, Lin–, Sca-1+ (KLS) population of hematopoietic stem 
and progenitor cells (HSPC) and of KLS,CD48+ short-term hematopoietic stem cells (ST-HSC). By contrast, 
there was a reduced frequency of KLS, CD48-, CD150hi long-term hematopoietic stem cells (LT-HSC), a 
population that is enriched upon normal physiological aging or serial transplantation and is associated with a 
preferential myeloid lineage repopulating potential (Supplemental Figure 6, A–E) (21).
In summary, germline KrasT58I expression results in defects in craniofacial development, myocardial 
hypertrophy, and hyperplastic growth of multiple other organs in adult animals. These mice therefore accu-
rately recapitulate a number of key RASopathy phenotypes (22, 23). KrasT58I/+ mice also develop an indo-
lent MPN that is fully penetrant and characterized by increased numbers of immature and differentiated 
myelomonocytic cells, erythroid abnormalities, and a reduced proportion of immunophenotypic BM HSC.
Abnormal lung development and neonatal death in CMV-Cre KrasLSL-P34R/+ mice. CMV-Cre KrasLSL-P34R/+ mice 
generated on a B6 strain background were born alive and were morphologically indistinguishable from 
their WT littermates (Supplemental Figure 7A). However, they almost universally developed cyanosis and 
respiratory failure by 30 minutes after birth and died soon thereafter (Supplemental Figure 7A). Genotyping 
the dead pups confirmed Cre-mediated recombination and excision of the LSL cassette (Supplemental Fig-
ure 1C). The only 2 CMV-Cre KrasLSL-P34R/+ mice (1 male and 1 female) that survived beyond the immediate 
perinatal period showed partial recombination of the Kras-LSL allele in tail DNA, which is consistent with 
somatic mosaicism (Supplemental Figure 7B). Both of these mice exhibited facial dysmorphia reminiscent 
of RASopathy syndromes, which was characterized by a wider separation between the eyes (Supplemental 
Figure 7C). The male mosaic mouse was fertile and produced pups that carried either the CMV-Cre trans-
gene or the unrecombined KrasLSL-P34R transgene but not the recombined KrasP34R transgene. Given the early 
lethality of CMV-Cre KrasLSL-P34R/+ mice and the survival of rare mosaic animals, we investigated whether 
the KRASP34R patients exhibit germline mosaicism. Sequencing fibroblast (n = 1) and/or leukocyte (n = 3) 
DNA samples from 3 patients with RASopathy with germline KRASP34R mutations revealed a heterozygous 
mutant allele frequency in all of them (Supplemental Figure 7D).
We examined sections of neonatal cardiopulmonary structures to investigate possible causes of myo-
cardial hypertrophy in KrasT58I/+ mice and perinatal lethality in CMV-Cre KrasLSL-P34R/+ pups (Figure 3). 
KrasT58I/+ neonates had normal heart anatomy, despite a modest decrease in pulmonary valve surface area 
(Figure 3). No obvious valvuloseptal abnormalities were evident in CMV-Cre KrasLSL-P34R/+ mice, but mor-
phometric analysis showed that the surface areas of the aortic, mitral, and tricuspid valves were increased, 
while the surface area of the pulmonary valve was decreased (Figure 3). Although statistically significant, 
these differences in valve areas in CMV-Cre KrasLSL-P34R/+ mice are modest and are unlikely to result in ear-
ly perinatal lethality. We also did not observe any significant variations in active (phosphorylated) ERK 
(p-ERK) staining in P0 heart sections across the 3 genotypes (Supplemental Figure 8).
The lungs of neonatal WT and KrasT58I/+ mice stained with H&E appeared normal histologically, 
with expanded air sacs (Figure 4A). By contrast, there was a striking lack of saccular inflation in the 
lungs of CMV-Cre KrasLSL-P34R/+ pups despite normal lobar septation (Figure 4A). Furthermore, immu-
nohistochemical and quantitative image analysis of p-ERK in lung sections that were counterstained 
with the specific endothelial cell marker isolectin B4, the membrane marker wheat germ agglutinin 
(WGA), and the nuclear (DNA) stain DAPI revealed localization of p-ERK in the plasma membrane 
for all 3 genotypes, with a significant increase in p-ERK signal in the membrane in neonatal CMV-Cre 
KrasLSL-P34R/+ lungs in comparison with WT and KrasT58I/+ tissues (Figure 4, B–F).
H&E staining of coronal sections from CMV-Cre KrasLSL-P34R/+ neonatal lungs revealed numerous large dilat-
ed airspaces throughout the periphery of the lungs (Figure 5A). Based on these observations, we reasoned that 
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differences in the lung phenotypes among WT, KrasT58I/+, and CMV-Cre KrasLSL-P34R/+ pups might be due to failure 
to appropriately modulate ERK activity during the sacculation phase of lung development (Figure 5B) (24, 25). 
To address this question, we isolated lungs from WT, KrasT58I/+, and CMV-Cre KrasLSL-P34R/+ embryos at E17.5, 
examined them morphologically, and performed immunohistochemical staining to measure p-ERK levels. 
Figure 3. Cardiac valve anatomy and surface areas in neonatal mice. (A) Representative images of heart cross sections stained with H&E. Dotted boxed 
areas indicate the aortic, pulmonary, mitral (blue) and tricuspid (black) valves of WT, KrasT58I/+, and CMV-Cre KrasLSL-P34R/+ animals. Scale bars: 1 mm. (B) 
Quantitation of heart valve areas in WT (dark blue circles), KrasT58I/+ (red squares), and CMV-Cre KrasLSL-P34R/+ (light blue triangles) neonatal mice. Statis-
tically significant differences between individual genotypes are shown and were evaluated by ordinary 1-way ANOVA with Tukey’s multiple comparisons 
test. (Note: the P value for the pulmonary valve areas of KrasT58I/+ animals is P = 0.0587.)
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While we observed similar lung histologies in all 3 genotypes at E17.5 (Figure 5C), the p-ERK staining patterns 
were markedly different. Specifically, whereas rare mesenchymal and epithelial cells stained positive for p-ERK 
in WT and KrasT58I/+ embryonic lungs (Figure 5, C and D), many more cells exhibited p-ERK expression in 
CMV-Cre KrasLSL-P34R/+ sections, with the most prominent staining visible in the epithelium around the bronchi-
oles near the proximal conducting airways (Figure 5E). Together, studies of neonatal CMV-Cre KrasLSL-P34R/+ mice 
Figure 4. Lung morphology and phosphorylated ERK staining in neonatal mice. (A) Representative neonatal lung tissue sections stained with H&E, 
showing poor lung inflation in CMV-Cre KrasLSL-P34R/+ (right) versus WT (left) or KrasT58I/+ (middle) neonates. (B) Immunohistochemical staining of repre-
sentative neonatal lung sections with wheat germ agglutinin (WGA) (white), DAPI (blue), isolectin B4 (red), and a phosphorylated ERK (p-ERK) antibody 
(green) demonstrated a thickened septum in CMV-Cre KrasLSL-P34R/+ lungs. (C–E) p-ERK colocalizes with WGA in the neonatal lungs for all 3 genotypes, and 
CMV-Cre KrasLSL-P34R/+ lungs showed an increased degree of p-ERK colocalization with WGA (E), which was quantified in F. Scale bar: 10 μM (C–E); 50 μM 
(B); 400 μM (A).Statistical significance was evaluated by 1-way ANOVA with Tukey’s multiple comparisons test.
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Figure 5. Morphology and p-ERK staining in E17.5 lung sections. (A) Representative H&E staining of coronal sections of neonatal WT and CMV-Cre 
KrasLSL-P34R/+ lungs (original magnification, ×40) shows dilated airspaces in the periphery of mutant lungs (black arrowheads). (B) Schematic depicting the 
stages of lung development, highlighting the saccular phase. (C–E) E17.5 sections from WT, KrasT58I/+, and CMV-Cre KrasLSL-P34R/+ E17.5 lungs showing H&E 
and p-ERK immunohistochemical staining (original magnification, ×10 [left] and ×40 [right]). Note that staining in the epithelial cells surrounding the 
bronchioles is only observed in CMV-Cre KrasLSL-P34R/+ lungs. Scale bar: 100 μM.
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and of E17.5 embryos support a model whereby aberrant MAPK activation in lung epithelial progenitor cells 
blocks normal lung sacculation and that this ultimately results in respiratory failure and neonatal death. These 
results also indicate that KrasT58I and KrasP34R mutations cause distinct MAPK spatial-temporal signaling proper-
ties in specific cell types within the developing cardiopulmonary system.
Hematopoiesis in Mx1-Cre KrasLSL-T58I/+ and Mx1-Cre KrasLSL-P34R/+ mice. The perinatal lethality of CMV-Cre 
KrasLSL-P34R/+ pups precluded directly comparing the cellular and biochemical consequences of KrasT58I and 
KrasP34R expression in adult mice. To circumvent this problem, we intercrossed KrasLSL-P34R/+ and KrasLSL-T58I/+ 
and Mx1-Cre mice on a B6 strain background. The Mx1 promoter was activated by injecting mice with 
a single intraperitoneal injection of polyinosinic-polycytidylic acid at weaning to stimulate endogenous 
interferon production and express the respective mutant alleles in interferon-responsive tissues, including 
HSCs and immature mesenchymal stem cells (26–28). This system has been widely used to investigate the 
functional consequences of individual gain- and loss-of-function mutations in the hematopoietic compart-
ment of genetically engineered mouse models, including KrasG12D and KrasA146T mice (25, 29). We confirmed 
recombination of the LSL cassette and expression of the respective Kras mutations in the blood leukocytes 
of Mx1-Cre KrasLSL-T58I/+ and Mx1-Cre KrasLSL-P34R/+ mice (Supplemental Figure 9).
Mx1-Cre KrasLSL-T58I/+ and Mx1-Cre KrasLSL-P34R/+ mice analyzed at 9–24 weeks of age had normal blood cell 
counts and modest splenomegaly (Figure 6A and Supplemental Table 3). By contrast, Mx1-Cre KrasLSL-G12D 
mice on this strain background consistently develop fatal MPN by this age, which is characterized by leukocy-
tosis, progressive anemia with ineffective erythropoiesis, and marked splenomegaly (29, 30). Flow cytometric 
analysis of the HSPC compartment (Supplemental Figure 10, A–E) revealed a modest increase in KLS cells, 
in KLS-CD48+ ST-HSC, and in multipotent progenitors (Supplemental Figure 10, B and C). By contrast, the 
KLS-CD48- LT-HSC compartment was reduced in Mx1-Cre KrasLSL-T58I/+ and Mx1-Cre KrasLSL-P34R/+ mice (Sup-
plemental Figure 10D) (31). Within the overall LT-HSC population, there was a reduction in the frequency 
and proportion of CD150hi cells (Supplemental Figure 10E) (32). These findings within the HSPC compart-
ment in mice in which KrasT58I and KrasP34R expression were induced at weaning are consistent with our studies 
in which KrasT58I was expressed in all tissues (Supplemental Figure 6).
The markedly attenuated hematologic disease phenotypes observed in Mx1-Cre KrasLSL-T58I/+ and Mx1-
Cre KrasLSL-P34R/+ mice relative to Mx1-Cre KrasLSL-G12D animals were associated with functional differences in 
HSPC. Specifically, c-kit+; Mac1– BM progenitors from Mx1-Cre KrasLSL-T58I/+ and Mx1-Cre KrasLSL-P34R/+ mice 
proliferated normally in liquid medium over a range of GM-CSF concentrations, whereas cells from Mx1-Cre 
KrasLSL-G12D/+ mice cultured in parallel exhibited excessive growth (Figure 6B).
Ras pathway activation and ex vivo growth of Mx1Cre KrasLSL-P34R/+ and Mx1Cre KrasLSL-T58I/+ mutant hemato-
poietic cells. To investigate signal transduction in primary cells expressing endogenous levels of K-RasP34R 
or K-RasT58I, we first used a Ras-binding domain (residues 1–149 of Raf1) peptide to pulldown Ras-GTP 
in Mac1+ BM cells from Mx1-Cre KrasLSL-P34R/+ and Mx1-Cre KrasLSL-T58I/+ mice. These cells were main-
tained in minimal medium without added cytokines (IMDM containing 1% bovine serum albumin) for 
5–7 hours (starve) and then exposed to a saturating dose of GM-CSF and FBS. Under these conditions, 
unstimulated Mac1+ cells from Mx1-Cre KrasLSL-T58I/+ mice exhibited modestly elevated Ras-GTP lev-
els that were substantially lower than those of  Mx1-Cre KrasLSL-G12D/+ cells analyzed in parallel (Figure 
6, C and D; see complete unedited blots in the supplemental material). Upon stimulation, Ras-GTP lev-
els increased dramatically in Mx1-Cre-KrasLSL-T58I/+ Mac1+ cells to levels comparable to those in Mx1-Cre 
KrasLSL-G12D/+ cells. By contrast, Ras-GTP levels in the Mac1+ BM cells of Mx1-Cre KrasLSL-P34R/+ mice were 
similar to those of WT cells under both starved and stimulated conditions. This almost certainly reflects the 
reduced binding affinity of K-RasP34R for Raf (12, 33, 34) rather than a true reduction in Ras-GTP levels, 
particularly as K-RasP34R accumulates in the GTP-bound conformation when overexpressed in cell lines (8).
Cytokine-starved Mac1+ cells from Mx1-Cre KrasLSL-P34R/+ and Mx1-Cre KrasLSL-T58I/+ mice had p-ERK and 
pAkt levels that were similar to those of  both WT and Mx1-Cre KrasLSL-G12D/+ cells. However, basal levels of 
pS6, which is downstream of both MAPK and PI3 kinase/Akt signaling in hematopoietic cells (30), were 
modestly elevated in the Mac1+ cells of Mx1-Cre KrasLSL-P34R/+ mice. Whereas Mac1+ cells of all 4 genotypes 
increased p-ERK, pAkt, and pS6 levels in response to GM-CSF stimulation, the p-ERK response was most 
robust in Mx1-Cre KrasLSL-T58I/+ cells, which is concordant with the large increase in Ras-GTP (Figure 6C).
Hematologic disease in Mx1-Cre KrasLSL-T58I/+ and Mx1-Cre KrasLSL-P34R/+ mice. Some Mx1-Cre KrasLSL-
T58I/+ and Mx1-Cre KrasLSL-P34R/+ mice developed systemic hematologic disease and became sick before 
12 months of age, and both mutant strains had a significantly shorter median survival (Figure 7A). We 
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euthanized moribund mice and analyzed their blood, BM, and spleens in parallel with the tissues of 
healthy age-matched WT littermates. Diseased Mx1-Cre KrasLSL-T58I/+ and Mx1-Cre KrasLSL-P34R/+ mice had 
significantly elevated blood leukocyte counts, with increased numbers of lymphocytes, neutrophils, and 
monocytes as well as mild anemia and splenomegaly (Figure 7, B and C, and Supplemental Table 4). 
Figure 6. Splenomegaly, cytokine responses, and signal transduction in the BM cells of 9- to 16-week-old Mx1-Cre KrasLSL-T58I/+ and Mx1-Cre KrasLSL-P34R/+ 
mice. (A) Spleen weights in WT, Mx1-Cre KrasLSL-T58I/+, and Mx1-Cre KrasLSL-P34R/+ mice. (B) Proliferation of WT, Mx1-Cre KrasLSL-T58I/+, Mx1-Cre KrasLSL-P34R/+, and 
Mx1-Cre KrasLSL-G12D/+ c-kit+; Mac1– progenitors exposed to a range of GM-CSF concentrations ex vivo. Two independent experiments were performed. (C) 
Western blot analysis of Mac1+ BM cells from age-matched mice of all 4 genotypes that were starved for 5–7 hours (time 0) and then stimulated with 20% 
FBS and 10 ng/mL GM-CSF for 7 minutes (time 7). The numbers below the bands indicate relative intensity of the band compared with the Hsp90 control 
from the same cell lysate. Representative images from 2 biological replicates are shown. (D) Ras-GTP, p-ERK, and p-S6 levels from at least 3 independent 
experiments are shown with the levels of each protein normalized to loading controls, and the data are presented as fold change from the WT time 0 
(basal) condition. Statistical significance was evaluated by 1-way ANOVA with Tukey’s multiple comparisons test.
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Pathologic examination revealed histiocytic sarcoma and lymphoma as the primary causes of death 
(Supplemental Table 5 and Supplemental Figure 11).
Interestingly, c-kit+; Mac1– progenitors cultured in liquid medium over a range of GM-CSF concen-
trations from sick mice showed variable sensitivity to cytokine stimulation (Supplemental Figure 12A). 
Hypersensitivity in this assay was also associated with cytokine-independent growth of BM myeloid pro-
genitor colonies in methylcellulose medium (Supplemental Figure 12B). We noticed that a pattern of 
abnormal growth in response to GM-CSF correlated with the extent and severity of hematologic disease 
and was most evident in mice with marked splenomegaly and lung infiltration (Supplemental Figure 12C).
Allelic imbalance is frequent in KRAS mutant cancers and can enhance competitive fitness and mod-
ulate sensitivity to targeted therapies (35). We quantitated the relative amounts of WT Kras to KrasP34R 
RNA transcripts in the BM of mice that died from hematologic disease (Supplemental Figure 12D). These 
studies did not reveal consistent allelic imbalance in mice with severe disease, as would be expected in the 
event of mutant gene amplifications or somatic uniparental disomy with loss of the WT Kras allele. These 
Figure 7. Reduced survival and hematologic disease in Mx1-Cre KrasLSL-T58I/+ and Mx1-Cre KrasLSL-P34R/+ mice. (A) Kaplan-Meier survival curve in cohorts 
of WT (n = 114), Mx1-Cre KrasLSL-T58I/+ (n = 37), and Mx1-Cre KrasLSL-P34R/+ (n = 37) B6 mice. Survival of Mx1-Cre KrasLSL-T58I/+ and Mx1-Cre KrasLSL-P34R/+ mice was 
similar and significantly reduced compared with that of congenic WT mice (P < 0.0001). (B) White blood counts (WBC) and (C) spleen weights of sick 
Mx1-Cre KrasLSL-T58I/+ and Mx1-Cre KrasLSL-P34R/+ mice. (D) Representative images and the number of cytokine-independent myeloid progenitor colonies grown 
from the BM of aged Mx1-Cre KrasLSL-T58I/+ and Mx1-Cre KrasLSL-P34R/+ mice. Colonies from WT and Mx1-Cre KrasLSL-G12D/+ mice are shown for comparison. Scale 
bar: 1000 μm. (E) GM-CSF dose-response liquid proliferation assay of c-kit+Mac1– BM progenitor cells of aged Mx1-Cre KrasLSL-T58I/+ and Mx1-Cre KrasLSL-P34R/+ 
mice, showing modest hypersensitivity in some animals. Statistical significance was evaluated by 1-way ANOVA with Tukey’s multiple comparisons test.
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data suggest that other mechanisms underlie the variable sensitivity of BM cells from diseased Mx1-Cre 
KrasLSL-T58I/+ and Mx1-Cre KrasLSL-P34R/+ mice to GM-CSF, which could include the acquisition of somat-
ic mutations in other genes or “feed-forward” autocrine/paracrine loops driven by cytokine production 
within the expanding population of myeloid cells.
Discussion
KRAS is the most frequently mutated oncogene in cancer, with 86% of  these somatic cancer-associated 
mutations introducing amino acid substitutions at glycine 12 (G12) and almost all of the remaining muta-
tions altering codons 13, 61, 117, or 146 (20). Ras oncoproteins with G12 substitutions show variable 
reductions in intrinsic GTPase activity and are insensitive to stimulation by neurofibromin and p120GAP, 
which are the predominant cellular GAPs (20, 36). Although individual K-Ras oncoproteins have widely 
been viewed as functionally equivalent, an elegant study recently showed that the higher basal output of 
K-RasG12D versus K-RasA146T has profound effects on tissue homeostasis, global and phospho-proteomic pro-
files, and tumorigenesis in mice (25). In addition to directly demonstrating that Ras-mediated phenotypes 
are strongly modulated by signaling thresholds that vary across different tissues, this work underscores the 
essential role of in vivo model systems characterized by endogenous gene expression for investigating the 
role of individual RAS mutations in human disease (37).
Germline KRAS codon 12 mutations are extremely rare in patients with RASopathy and are associated 
with very severe phenotypes, whereas substitutions in codons 61, 117, and 146 have not been reported 
(https://nseuronet.com/php/about.php). The largely nonoverlapping spectra of somatic and germline 
KRAS mutations likely reflect the fact that — on one hand — widespread expression of the highly activated 
K-Ras proteins specified by cancer-associated somatic mutations severely compromises embryonic viability 
and — on the other — most RASopathy proteins are insufficiently potent to drive clonal outgrowth and 
malignant transformation. This latter idea is consistent with the moderately increased incidence of can-
cer in patients with RASopathy, with the spontaneous regression of the JMML-like MPN that develops 
in some infants with NS and with molecular analyses showing that, when patients with germline HRAS 
mutations develop sarcomas, these tumors frequently exhibit somatic uniparental disomy with duplication 
of mutant HRAS and loss of the corresponding normal allele (4, 7, 38, 39). With the KrasV14I strain reported 
previously (9), the KrasP34R and KrasT58I mice described here are robust models for comparing the biochem-
ical and functional consequences of expressing endogenous levels of specific KRAS mutations in different 
tissues and for testing targeted agents at distinct developmental stages.
Our in vivo data support the following order with respect to the basal output of individual K-Ras rasopa-
thy mutant proteins: P34R > T58I > V14I; this is generally consistent with biochemical studies of the respec-
tive recombinant proteins, their effect on embryonic viability, and the relative sensitivity of myeloid progen-
itor cells to GM-CSF (7, 8). Whereas widespread KrasP34R expression causes perinatal lethality, heterozygous 
(but not homozygous) KrasT58I mutant mice live to adulthood. By contrast, both heterozygous and homozy-
gous KrasV14I mice are viable (9). KrasT58I/+ and KrasV14I/V14I mice — as well as rare mosaic KrasP34R/+ mice — 
exhibit RASopathy-like craniofacial abnormalities, and we identified synostosis of the coronal and interfron-
tal sutures as potential contributing factors. The attenuated phenotype in KrasV14I/+ mice demonstrates gene 
dosage effects on craniofacial development that likely result from lower signal of output from K-RasV14I versus 
K-RasT58I in susceptible target cells. Hernández-Porras et al. (9) reported cardiac hypertrophy in 4-month-old 
KrasV14I/V14I mice that was not present in age-matched KrasV14I/+ animals, but was similar to what we detected 
in the hearts of older KrasT58I/+ animals. We also observed testicular and renal hypertrophy at this time point. 
Similarly, KrasV14I/+, KrasV14I/V14I, and KrasT58I/+ mice all developed a JMML-like MPN with evidence of gene 
dosage effects with respect to disease severity and survival (9).
Our studies of CMV-Cre KrasLSL-P34R/+ mice provide insights into the key role of K-Ras signaling at discrete 
stages of lung morphogenesis. Germline expression of KrasG12D caused abnormal lung branching as early as 
E11.5 that was associated with the formation of large, fluid-filled sacs in place of normal terminal branches 
(40). Subsequent targeted expression of KrasG12D to the airway epithelium resulted in a defect in airway shape 
change at E11.75, which was associated with an abnormal tissue distribution of p-ERK (41). In utero treat-
ment with the MEK inhibitor PD0325901 reversed this defect and highlighted the importance of MAPK 
signaling in regulating lung development (41). Inducing KrasG12D expression in lung progenitors at E15 with a 
Sox9CreER driver caused a general expansion of the epithelium that generated large sac-like structures instead of 
the fine branching alveolar network (42). This phenotype is consistent with the sacculation defect we observed 
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in CMV-Cre KrasLSL-P34R/+ neonates and with elevated p-ERK staining within the epithelium around the bron-
chioles at E17.5. Together, these data suggest that the increased output of K-RasP34R does not reach the thresh-
old required to disrupt lung branching at E11–12 and that the later stages of sacculation and alveolar differ-
entiation are exquisitely sensitive to MAPK signaling. The effects of endogenous K-RasG12D and K-RasP34R 
expression at different stages of lung morphogenesis are reminiscent of data showing that colonic Paneth cells 
are absent in K-RasG12D, but not K-RasA146T, mice and were restored by treatment with a MEK inhibitor (25, 
43). The prominent role of K-Ras signaling in cell fate decisions in the developing lung is also consistent with 
the observation that stochastic activation of a latent KrasG12D allele efficiently initiates lung tumorigenesis (44).
Within the hematopoietic compartment, comparative studies of KrasT58I/+, Mx1-Cre KrasLSL-T58I/+, and Mx1-
Cre KrasLSL-P34R/+ mice showed that all 3 models demonstrated a significant reduction in the BM LT-HSC popu-
lation. The even more attenuated and highly proliferative HSC compartment of Mx1-Cre KrasLSL-G12D mice (45) 
supports the hypothesis that elevated K-Ras output promotes proliferation and differentiation at the expense of 
HSC self-renewal. Despite these similarities in HSPC populations, KrasT58I expression throughout embryonic 
development consistently induced MPN, while Mx1-Cre; KrasT58I mice had a less penetrant and more indolent 
phenotype. Potential explanations for these observations include more deleterious consequences of expressing 
KrasT58I in the developing hematopoietic system, effects of strain background, and/or possible involvement of 
nonhematopoietic cells in which Mx1-Cre is inactive in promoting hematologic disease in germline mutant mice.
The availability of mice harboring 3 different conditional Kras mutant alleles on the same B6 strain back-
ground (KrasLSL-P34R, KrasLSL-T58I, and KrasLSL-G12D) allowed us to directly compare the cell biologic and biochemical 
consequences of expressing physiologic levels of the respective proteins in defined populations of primary BM 
cells, with the caveat that interpreting Ras-GTP data from Mx1-Cre KrasLSL-P34R/+ BM cells is problematic, because 
of the reduced affinity of K-RasP34R for the Raf1 Ras-binding domain peptide used in the pulldown assay (12, 
33, 34). We found that c-kit+; Mac1– BM progenitors from Mx1-Cre KrasLSL-G12D mice were hyperproliferative 
over a range of GM-CSF concentrations, whereas cells from WT, Mx1-Cre KrasLSL-P34R, and Mx1-Cre KrasLSL-T58I 
mice exhibited similar growth properties. Biochemical analysis of Mac1+ ells under basal (starved) conditions 
and upon exposure to a saturating dose of GM-CSF similar to that used in the liquid proliferation assay revealed 
discrete effects of endogenous expression of each K-Ras mutant protein. In comparison with WT Mac1+ cells, 
basal Ras-GTP levels were modestly and markedly elevated in Mx1-Cre KrasLSL-T58I/+ and Mx1-Cre KrasLSL-G12D/+ 
cells, respectively. Interestingly, GM-CSF stimulation induced a much greater increase in Ras-GTP levels in 
Mx1-Cre KrasLSL-T58I/+ Mac1+ cells than in control WT cells. Whereas WT and Mx1-Cre KrasLSL-G12D/+ Mac1+ cells 
exhibited generally similar patterns of ERK activation in response to cytokine stimulation, Mx1-Cre KrasLSL-T58I/+ 
cells markedly increased p-ERK levels in parallel with the induction of Ras-GTP. Interestingly, the Mac1+ BM 
cells of Mx1-Cre KrasLSL-P34R/+ mice showed a similar p-ERK response to GM-CSF as WT and Mx1-Cre KrasLSL-
G12D/+ cells. Based on these data (and in the absence of meaningful Ras-GTP data from the KrasLSL-P34R strain), we 
speculate that the higher intrinsic output of K-RasP34R and K-RasG12D induced greater levels of negative feedback 
than K-RasT58I and that this, in turn, partially restrained Ras and downstream effector activation in response to 
acute cytokine stimulation (46). Furthermore, the contrast between the aggressive MPN that develops in Mx1-
Cre KrasLSL-G12D mice and the indolent disease phenotype in Mx1-Cre KrasLSL-P34R animals suggests that compensa-
tory mechanisms fail in the former and are effective in preserving near-normal tissue homeostasis in the latter.
In summary, the KrasP34R and KrasT58I mouse strains described here provide what we believe to be new in 
vivo models for elucidating how germline and somatic KRAS mutations perturb cell fate decisions and con-
tribute to human developmental disorders and cancer. Table 1 compares selected findings in these mice and 
in the other 4 strains of Kras knock-in mice reported to date (6, 9, 25, 29, 40, 47). KrasLSL-P34R/+ and KrasLSL-T58I/+ 
mice are valuable models for performing preclinical studies of MEK inhibitors and other potential therapies 
for reversing or preventing severe and life-threatening complications in patients with RASopathy. Indeed, 2 
young children with severe hypertrophic cardiomyopathy were recently reported who improved after receiv-
ing a MEK inhibitor (48). In light of the ethical and practical complexities inherent in conducting clinical 
trials in vulnerable populations of young children, preclinical data from genetically accurate animal models, 
such as the ones described here, may play a key role in informing translation.
Methods
Further information can be found in the Supplemental Methods.
μ-CT. Following euthanasia, crania of WT and T58I mice at 8 months were imaged using the Scanco μCT 
50 scanner (Scanco Medical AG) with 17.2 μm voxel size and X-ray energies of 55 kVp and 109 μA. Images 
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were reconstructed and converted to 3D volumes (μCT Evaluation Program V6.5-3) and reference landmarks 
according to Vora et al. (49) were placed manually on the rendered data using the Avizo-lite 3D analysis software. 
All landmarks were digitized by the same investigator for a total of 18 landmarks (see Supplemental Figure 3).
Pathologic examination, tissue processing, and staining. Mice were either euthanized at a specific age or 
observed for signs of disease and were killed when moribund. Cardiac blood was obtained in Microvet EDTA 
tubes (BD Biosciences) for complete blood cell counts using a Hemavet 850FS (Drew Scientific), and BM cyto-
spins were prepared using a Shandon Cytospin 3 Cytocentrifuge (Thermo Fisher Scientific). Blood smears and 
BM cytospins were stained with Wright-Giemsa Stain (Fisher Healthcare PROTOCOL) following standard 
protocols. Images were taken on a Nikon Eclipse 80i microscope with a Nikon Digital Sight camera using NIS- 
Elements F2.30 software at a resolution of 2560 × 1920 pixels. Using Adobe Photoshop CS2, image quality 
was improved with unsharp mask, and images were resized and set at a resolution of 300 pixels/inch.
Organs were collected in Z-fix (Anatech Ltd). Mouse sternums were decalcified using Cal-Rite (Rich-
ard-Allan Scientific). Tissue sections of fixed solid organs were embedded in paraffin and sectioned at 4 μm 
thickness and processed following standard procedures for the sectioning of paraffin blocks. H&E stainings 
were processed on the Leica Autostainer XL according to manufacturer’s instructions. Masson’s trichrome 
stainings were performed using the Masson’s trichrome 2000 Stain Kit (American MasterTech) following 
the manufacturer’s instructions. p-ERK immunostaining was performed with the anti–p-MAPK (Erk1/2) 
antibody (Cell Signaling Technology, 4370, 1:400) using the Discovery Ultra automated slide stainer (Ven-
tana) following the manufacturer’s instructions. Tissue processing, sectioning, and staining were performed 
by the Biorepository and Tissue Biomarker Technology Core at the University of California, San Francis-
co, Helen Diller Family Comprehensive Cancer Center. Images were taken and analyzed on a Keyence 
BZ-X800E. For cardiac analysis, Z-fix (Anatech Ltd.) fixed and paraffin-embedded fetuses were sectioned 
Table 1. Selected features of heterozygous germline and somatic knock-in Kras mutant alleles in mice
V14I P34R T58I A146T G12D G12V






in some blood 
cancers
Infrequent somatic 
mutation, mostly in 
GI cancers
Most common 
somatic mutation in 
cancer





due to defects in 
lung sacculation 
defect — some 
mosaic mice reach 
adulthood
Viable ND
Lethal by E11.5 
due to placental 
trophoblast defect
Lethal by E13.5 — 
some mosaic mice 
reach adulthood
Heart Cardiac hyperplasia by age 4 months
Mild changes in 
valve surface areas 
in neonatal mice
HCM in adults ND VSDs by E13.5 in Meox2Cre embryos ND
Lung development ND
Perinatal lethality 





E11.5 in Meox2Cre 
embryos; expanded 





Hematopoietic Indolent JMML-like MPN




Indolent MPN in 
KrasT58I/+ mice; 




Mx1Cre mice all 
developed MPNs 
that were less 




defects in Meox2Cre 
embryos at E12.5; 
Mx1Cre mice showed 
aggressive MPN




Reference(s) ref. 9 This study This study ref. 25 refs. 6, 29, 40, 41, 42 ref. 47
Comparisons are between heterozygous mutant embryos/mice for each allele on 1 or more strain backgrounds. Phenotypes in different Cre strain 
background are indicated. ND, not determined; B6, C57BL/6; 129, 129 substrain; HCM, hypertrophic cardiomyopathy; VSD, ventricular septal defect; JMML, 
juvenile myelomonocytic leukemia; MPN, myeloproliferative neoplasm.
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transversally at 6 μm and H&E staining following standard protocols by Histology Core Facility at National 
Center for Cardiovascular Research, Spain. p-ERK fluorescence staining was performed with anti–p-MAPK 
(Erk1/2) antibody (Cell Signaling Technology, 4370, 1:200). We unmasked antigens with sodium citrate 
treatment. Fluorescence signal was amplified with the Tyramide Signal Amplification Kit (PerkinElmer, 
NEL744, 1:100) and counterstained with DAPI, Isolectin B4–Alexa Fluor 647 (Thermo Fisher Scientific, 
1:200) and WGA, Tetramethylrhodamine Conjugate (Thermo Fisher Scientific, W849, 1:100). Images were 
taken with a Leica SP8 Confocal microscope. p-ERK quantification (fraction of WGA+ signal overlapping 
with p-ERK signal in single optical sections) was performed with the JACoP tool from Fiji Software (Open 
Source) to calculate Manders’ overlap coefficient based on the Pearson’s correlation coefficient using thresh-
old (n = 3 fetuses per genotype). P values were calculated with an ordinary 1-way ANOVA analysis without 
repeated measures and Tukey’s multiple comparisons test.
BM isolation and colony-forming, proliferation, and biochemical analysis. Nucleated BM cells were harvested 
from 1 arm bone into IMDM + 2% FBS for colony assay and cytospin. BM cells from the femora, tibiae, 
hips, and the other arm of the mice were harvested into PBS, pH 7.2, 0.5% BSA, and 2 mM EDTA and 
enriched for Mac1+ cells by magnetic cell sorting using CD11b Microbeads and LS columns (Miltenyi Biotec) 
according to the manufacturer’s protocol. This fraction is used for biochemical assays. Mac1– cells from this 
selection were then stained with CD117 microbeads (Miltenyi Biotec, 130-091-224) and positively selected on 
the MS columns to enrich for c-kit+; Mac1– cells, which were used for the liquid proliferation assay.
For myeloid progenitor colony growth (CFU-GM) assays, 1.5 × 105 nucleated BM cells per plate were plat-
ed in 1.5 mL M3231 methylcellulose medium (StemCell Technologies) without any cytokines. Colonies were 
enumerated after 7 days. Images of colonies were taken using the EVOS cell imaging system at a magnification 
of ×10 (scale bar: 1000 μm; Figure 7D).
One hundred thousand c-kit+; Mac1– cells per well were plated in 1 mL Iscove’s Modified Dulbec-
co’s Medium (Gibco, Thermo Fisher) containing 10% FBS (Hyclone), 2 mM L-glutamine (Gibco Life 
Technologies), 100 U Penicillin-Streptomycin (Gibco Life Technologies), 0.05 mM β-mercaptoethanol 
(MilliporeSigma), and varying amounts of GM-CSF (PeproTech). Cells were incubated in a humidi-
fied incubator at 37°C with 5% CO2. Cells were counted using a Vi-CELL XR Cell Counter (Beckman 
Coulter) 3 days after culture.
For biochemical studies, equal numbers of Mac1+ cells were used for each condition within the same 
experiment, and at least 11 million cells were used. Cells were resuspended in IMDM + 1% bovine serum 
albumin at 107 cells/mL after isolation using CD11b beads as described above and incubated in a humidi-
fied incubator at 37°C with 5% CO2 until 5–7 hours after sacrifice. Stimulated cells were treated with 20% 
FBS (Hyclone) and 10 ng/mL GM-CSF (PeproTech) and returned to the incubator for 7 minutes. Cells 
from all conditions were then washed once with PBS, followed by one Tris-buffered saline wash, and lysed 
with the Lysis buffer supplied by the Active Ras Pull-Down and Detection Kit (Thermo Scientific) and 
Halt protease and phosphatase inhibitor (Thermo Scientific, 78440; 1:100). Between 12 and 16 μg whole 
cell lysates were used to assess for downstream effectors, using the following antibodies: anti-Ras antibody 
(Thermo Scientific, 16117; 1:200), rabbit anti–p-ERK (CST 4370; 1:1000); mouse anti-ERK (CST 9107; 
1:1000); rabbit anti-pAkt S473 (CST 4060; 1:2000); mouse anti-Akt (CST 2966; 1:2000); rabbit anti-pS6 
(CST 4858; 1:1000); mouse anti-S6 (CST 2317; 1:1000); and mouse anti-Hsp90 (BD 610418; 1:10,000). 
The rest of the whole cell lysates (at least 250 μg) was used to detect Raf1 binding levels using the Active 
Ras Pull-Down and Detection Kit (Thermo Scientific) according to the manufacturer’s protocols. Quanti-
tation was performed using the ImageLab (Bio-Rad) software.
Heart valve surface area quantitation. Leaflet area was obtained from H&E-stained sections. Area of freehand 
outline valve leaflets from at least 8 sections of 3 fetuses was measured with Measurements tool (Fiji Software).
Mice. The mice described in this report are available through the Jackson Laboratory Repository. The 
relevant identifiers are as follows: JAX035731 (LSL-T58I) and JAX035732 (LSL-P34R).
Statistics. Statistical analyses were carried out using Prism 7 (GraphPad). Data are presented as mean ± 
SEM unless stated otherwise. Statistical significance was determined by performing 2-tailed, unpaired Stu-
dent’s t tests when comparing 2 groups. Ordinary 1-way ANOVA analysis without repeated measures and 
Tukey’s multiple comparisons test was used to compare 3 or more groups. Survival analysis was performed 
using the Kaplan-Meier method. P values of  less than 0.05 are considered significant.
Study approval. All animal procedures described in this manuscript were approved by the University of 
California, San Francisco, Institutional Animal Care and Use Program.
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